| Oct 8 |
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
|
| Sep 5 |
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 19 |
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
|
| Aug 17 |
Talphera First Half 2024 Earnings: US$0.31 loss per share (vs US$0.40 loss in 1H 2023)
|
| Aug 14 |
Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript
|
| Aug 14 |
AcelRx Pharmaceuticals GAAP EPS of -$0.15 beats by $0.06
|
| Aug 14 |
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
|
| May 20 |
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
| May 16 |
Talphera to Participate at A.G.P. Virtual Healthcare Conference
|
| May 14 |
Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript
|
